DualityBio secures $1B Genentech ADC deal for DUPAC platform

Key Takeaways:

DualityBio receives $45 million upfront from Genentech for next-generation ADCs
Potential milestone payments exceed $1 billion plus tiered royalties
Genentech takes over development and commercialization after Phase 1a

DualityBio (HKEX: 09606) has struck a global collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates built on its proprietary DUPAC payload platform, a deal worth more than $1 billion in potential milestones that hands the Hong Kong-listed biotech a $45 million upfront payment.

"By combining DualityBio's payload innovation and early-stage global clinical development capabilities with Genentech's deep oncology expertise and worldwide development reach, we can advance these programs with greater speed and scale and bring differentiated medicines to more patients around the world," Dr. John Zhu, founder and chief executive officer of DualityBio, said.

Under the terms, DualityBio will lead discovery and early global clinical development of ADCs against Genentech-defined oncology targets until Phase 1a trials complete, after which Genentech receives an exclusive worldwide license and sole responsibility for further clinical development and commercialization. DualityBio is also eligible for tiered royalties on annual net sales of any approved products. Shares rose 2.5 percent on the announcement, with short selling at $9.29 million, a 9.6 percent ratio.

The deal centers on DUPAC, one of four ADC platforms DualityBio has built alongside DITAC, DIMAC and DIBAC. DUPAC encompasses payloads including DUP5, DUP9 and DUP10, each acting through a distinct antitumor mechanism, engineered for high potency, broad-spectrum activity, short systemic half-life and a bystander effect suited to heterogeneous solid tumors. The platform is designed to retain antitumor activity in tumors resistant or less responsive to topoisomerase inhibitor-based ADCs, the payload class underlying most approved ADCs today, which are moving into earlier lines of therapy across major solid tumor indications.

DUPAC data and the resistance problem

Preclinical data on DUP5- and DUP9-based ADCs, including activity in tumor models relatively insensitive to topoisomerase inhibitor payloads and non-human primate tolerability, have been presented at AACR 2025, the AACR-NCI-EORTC International Conference 2025 and AACR 2026. The collaboration pairs DualityBio's payload innovation with Genentech's oncology reach, a combination that addresses a growing unmet need as patients progress on existing ADC payload classes.

"Backed by Roche's decades-long legacy in oncology, collaborating with partners such as DualityBio enables us to identify novel treatment options, such that we can tackle patients' unmet needs in cancer care," Boris L. Zaïtra, head of Roche Corporate Business Development, said.

Investor implications

The agreement is a de-risking event for DualityBio, which is conducting global, multicenter trials across nearly 20 countries with more than 3,500 patients enrolled. The $45 million upfront extends the company's cash runway, while the more than $1 billion in potential milestones and tiered royalties offer upside not previously reflected in its valuation. The deal also signals confidence in DualityBio's platform from one of the largest oncology developers, a validation that could lift sentiment across the broader ADC sector, including peers such as Daiichi Sankyo and AstraZeneca, which have built their own topoisomerase inhibitor-based ADC franchises.

DualityBio cautioned under Rule 18A.05 of the Listing Rules that there is no assurance it will ultimately develop, market or commercialize its core products successfully. The company's shares trade on the Hong Kong Stock Exchange under the ticker 09606.

This article is for informational purposes only and does not constitute investment advice.